期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 82, 期 2, 页码 157-166出版社
WILEY
DOI: 10.1038/sj.clpt.6100258
关键词
-
资金
- Medical Research Council [G0600621] Funding Source: Medline
- Medical Research Council [G0600621] Funding Source: researchfish
- MRC [G0600621] Funding Source: UKRI
Robust tools for monitoring the safety of marketed therapeutic products are of paramount importance to public health. In recent years, innovative statistical approaches have been developed to screen large post- marketing safety databases for adverse events (AEs) that occur with disproportionate frequency. These methods, known variously as quantitative signal detection, disproportionality analysis, or safety data mining, facilitate the identification of new safety issues or possible harmful effects of a product. In this article, we describe the statistical concepts behind these methods, as well as their practical application to monitoring the safety of pharmaceutical products using spontaneous AE reports. We also provide examples of how these tools can be used to identify novel drug interactions and demographic risk factors for adverse drug reactions. Challenges, controversies, and frontiers for future research are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据